Search

Introduction Strong evidence of neurobiological effects in clinical trials could facilitate the development of new treatments for Alzheimer’s disease. It is expected that cohorts of ~100 prodromal subjects per arm are required to obtain significant results with both vMRI and more recently developed methods such as Diffusion Tensor Imaging (DTI) and resting state functional Magnetic Resonance Imaging (rs-fMRI). For time-efficient trial execution, multi-center studies are required to provide rapid enrollment, however the collection of robust data across different scanner types and is essential. The second phase of the Alzheimer’s Disease Neuroimaging Initiative (ADNI-2) has established 3T DTI and rs-fMRI sequence parameters for GE and Philips systems only, respectively. Our objective was to implement these sequences on Philips, Siemens, and GE scanners and to evaluate their consistency prior to their use in a multi-center clinical trial.